Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?
We present a case of a patient with a three-month history of peripheral blood cytopenia without a confirmed diagnosis of myelodysplastic syndrome, who developed a favourable-risk acute myeloid leukemia (AML), according to the European Leukemia Net (ELN) criteria. The patient achieved a complete remi...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2019/3914828 |
id |
doaj-382c0d489cd9414f8b51a0a43665bb6c |
---|---|
record_format |
Article |
spelling |
doaj-382c0d489cd9414f8b51a0a43665bb6c2020-11-24T21:29:14ZengHindawi LimitedCase Reports in Hematology2090-65602090-65792019-01-01201910.1155/2019/39148283914828Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?M. Malagola0N. Polverelli1V. Cancelli2E. Morello3A. Turra4E. Borlenghi5F. Cattina6B. Rambaldi7S. Bernardi8C. Zanaglio9Elif Dereli Eke10L. Gandolfi11M. Farina12D. Russo13Chair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyChair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyChair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyChair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyChair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyUnit of Hematology, ASST-Spedali Civili, Brescia, ItalyChair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyChair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyChair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyChair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyChair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyChair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyChair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyChair of Hematology, Department of Clinical and Surgical Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili, Brescia, ItalyWe present a case of a patient with a three-month history of peripheral blood cytopenia without a confirmed diagnosis of myelodysplastic syndrome, who developed a favourable-risk acute myeloid leukemia (AML), according to the European Leukemia Net (ELN) criteria. The patient achieved a complete remission with incomplete platelet recovery (CRi) after induction. The patient achieved the morphological CR after the first consolidation and completed the first-line treatment with a syngeneic stem cell transplantation (SCT). A disease relapse occurred after one year of CR (blast cell count in the bone marrow 15%), and the patient was offered a haplo-SCT, which he refused due to personal reasons. In this paper, we discuss the interplay between clinical and biological risk factors in non-high-risk AML patients and speculate that some old clinical risk factors (e.g., age of the patient, achievement of CR after induction, and previous history of myelodysplastic syndrome) may still impact on the treatment decision algorithm of some of these patients.http://dx.doi.org/10.1155/2019/3914828 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
M. Malagola N. Polverelli V. Cancelli E. Morello A. Turra E. Borlenghi F. Cattina B. Rambaldi S. Bernardi C. Zanaglio Elif Dereli Eke L. Gandolfi M. Farina D. Russo |
spellingShingle |
M. Malagola N. Polverelli V. Cancelli E. Morello A. Turra E. Borlenghi F. Cattina B. Rambaldi S. Bernardi C. Zanaglio Elif Dereli Eke L. Gandolfi M. Farina D. Russo Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? Case Reports in Hematology |
author_facet |
M. Malagola N. Polverelli V. Cancelli E. Morello A. Turra E. Borlenghi F. Cattina B. Rambaldi S. Bernardi C. Zanaglio Elif Dereli Eke L. Gandolfi M. Farina D. Russo |
author_sort |
M. Malagola |
title |
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? |
title_short |
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? |
title_full |
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? |
title_fullStr |
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? |
title_full_unstemmed |
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? |
title_sort |
biological versus clinical risk factors in acute myeloid leukemia: is there a winner? |
publisher |
Hindawi Limited |
series |
Case Reports in Hematology |
issn |
2090-6560 2090-6579 |
publishDate |
2019-01-01 |
description |
We present a case of a patient with a three-month history of peripheral blood cytopenia without a confirmed diagnosis of myelodysplastic syndrome, who developed a favourable-risk acute myeloid leukemia (AML), according to the European Leukemia Net (ELN) criteria. The patient achieved a complete remission with incomplete platelet recovery (CRi) after induction. The patient achieved the morphological CR after the first consolidation and completed the first-line treatment with a syngeneic stem cell transplantation (SCT). A disease relapse occurred after one year of CR (blast cell count in the bone marrow 15%), and the patient was offered a haplo-SCT, which he refused due to personal reasons. In this paper, we discuss the interplay between clinical and biological risk factors in non-high-risk AML patients and speculate that some old clinical risk factors (e.g., age of the patient, achievement of CR after induction, and previous history of myelodysplastic syndrome) may still impact on the treatment decision algorithm of some of these patients. |
url |
http://dx.doi.org/10.1155/2019/3914828 |
work_keys_str_mv |
AT mmalagola biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT npolverelli biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT vcancelli biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT emorello biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT aturra biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT eborlenghi biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT fcattina biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT brambaldi biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT sbernardi biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT czanaglio biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT elifderelieke biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT lgandolfi biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT mfarina biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner AT drusso biologicalversusclinicalriskfactorsinacutemyeloidleukemiaisthereawinner |
_version_ |
1725966724886429696 |